- Home
- TURN vs NKGN Comparison
TURN vs NKGN Comparison
Compare TURN & NKGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- NKGN
- Stock Information
- Founded
- TURN 1981
- NKGN 2017
- Country
- TURN United States
- NKGN United States
- Employees
- TURN N/A
- NKGN N/A
- Industry
- TURN Finance/Investors Services
- NKGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TURN Finance
- NKGN Health Care
- Exchange
- TURN Nasdaq
- NKGN Nasdaq
- Market Cap
- TURN 33.4M
- NKGN 8.1M
- IPO Year
- TURN N/A
- NKGN N/A
- Fundamental
- Price
- TURN $3.21
- NKGN $0.42
- Analyst Decision
- TURN
- NKGN
- Analyst Count
- TURN 0
- NKGN 0
- Target Price
- TURN N/A
- NKGN N/A
- AVG Volume (30 Days)
- TURN 8.1K
- NKGN 2.6M
- Earning Date
- TURN 11-11-2024
- NKGN 11-12-2024
- Dividend Yield
- TURN N/A
- NKGN N/A
- EPS Growth
- TURN N/A
- NKGN N/A
- EPS
- TURN N/A
- NKGN N/A
- Revenue
- TURN $129,297.00
- NKGN N/A
- Revenue This Year
- TURN N/A
- NKGN N/A
- Revenue Next Year
- TURN N/A
- NKGN N/A
- P/E Ratio
- TURN N/A
- NKGN N/A
- Revenue Growth
- TURN 6.32
- NKGN N/A
- 52 Week Low
- TURN $3.16
- NKGN $0.20
- 52 Week High
- TURN $4.47
- NKGN $5.10
- Technical
- Relative Strength Index (RSI)
- TURN 31.67
- NKGN 48.24
- Support Level
- TURN $3.21
- NKGN $0.20
- Resistance Level
- TURN $3.28
- NKGN $0.65
- Average True Range (ATR)
- TURN 0.05
- NKGN 0.11
- MACD
- TURN -0.01
- NKGN 0.03
- Stochastic Oscillator
- TURN 25.67
- NKGN 31.78
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About NKGN NKGen Biotech Inc.
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.